ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2767

Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study

Shafay Raheel1, Cynthia S. Crowson2 and Eric L. Matteson3, 1St. Joseph's Hospital, Chicago, IL, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: polymyalgia rheumatica, population studies and risk

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The presence of varicella zoster virus (VZV) signal in the temporal arteries of patients with giant cell arteritis has suggested a possible role of VZV in triggering the immunopathology of GCA. This calls into question whether VZV may also play a role in the development of polymyalgia rheumatic (PMR). We aimed to determine whether herpes zoster (HZ) infection is a risk factor for PMR.

Methods: All incident cases of PMR in a geographically-defined area diagnosed between 1990 and 2014 were identified. For each patient with PMR, a non-PMR control subject matched on age and sex was randomly selected from the same underlying population. Each control was assigned an index date corresponding to the PMR incident date of the matched case. The medical records of all patients with codes for HZ were reviewed to confirm the incident date and diagnosis.

Results:

The study included 541 patients with PMR and 541 subjects without PMR. The average age at PMR incidence (index date for the non-PMR cohort) was 74 years, and 349 (65%) subjects were female in each cohort. Prior to index date, 61 (11%) patients with PMR and 62 (11%) non-PMR patients had HZ infection (p=0.92).

Conclusion: Herpes zoster infection was not associated with an increased risk of PMR. Further work is needed to determine the etiology of PMR.


Disclosure: S. Raheel, None; C. S. Crowson, None; E. L. Matteson, None.

To cite this abstract in AMA style:

Raheel S, Crowson CS, Matteson EL. Herpes Zoster As a Risk Factor for Polymyalgia Rheumatica: A Population-Based Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/herpes-zoster-as-a-risk-factor-for-polymyalgia-rheumatica-a-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/herpes-zoster-as-a-risk-factor-for-polymyalgia-rheumatica-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology